[1]Vogelstein   B,   Kinzler   KW.   Cancer   genes   and   the   pathways   they   control .   Nat   Med .   2004 Aug;10(8):789-99 .

[2]Reid  MA,  Dai  Z,  Locasale  JW.  The  impact  of  cellular  metabolism  on  chromatin  dynamics  and epigenetics . Nat Cell Biol . 2017 Nov;19(11):1298- 1306 .

[3]Schmidt DR, Patel R, Kirsch DG, Lewis CA, Vander Heiden MG, Locasale JW. Metabolomics in cancer research and emerging applications in clinical oncology. CA Cancer J Clin . 2021 Jul;71(4):333-358 . 

[4]NEUMAN RE, MCCOY TA . Dual requirement of Walker carcinosarcoma 256 in vitro for asparagine and glutamine . Science . 1956 Jul 20;124(3212):124-5 .

[5]Clavell LA, Gelber RD, Cohen HJ, Hitchcock- Bryan S, Cassady JR, Tarbell NJ, Blattner SR, Tantravahi R, Leavitt P, Sallan SE . Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia . N Engl J Med . 1986 Sep 11;315(11):657-63 .

[6]Dwarakanath BS, Singh D, Banerji AK, Sarin R, Venkataramana NK, Jalali R, Vishwanath PN, Mohanti BK, Tripathi RP, Kalia VK, Jain V. Clinical studies for improving radiotherapy with 2-deoxy- D-glucose: present status and future prospects . J Cancer Res Ther. 2009 Sep;5 Suppl 1:S21-6 .

[7]Raez LE, Papadopoulos K, Ricart AD, Chiorean EG, Dipaola RS, Stein MN, Rocha Lima CM, Schlesselman JJ, Tolba K, Langmuir VK, Kroll S, Jung DT, Kurtoglu M, Rosenblatt J, Lampidis TJ. A phase I dose-escala- tion trial of 2-deoxy- D-glucose alone or combined with docetaxel in patients with advanced solid tumors . Cancer Chemother Pharmacol . 2013 Feb;71(2):523-30 .

[8]Altman BJ, Stine ZE, Dang CV. From Krebs to clinic: glutamine metabolism to cancer therapy. Nat Rev Cancer. 2016 Nov;16(11):749 .

[9]Xiang Y, Stine ZE, Xia J, Lu Y, O'Connor RS, Altman BJ, Hsieh AL, Gouw AM, Thomas AG, Gao P, Sun L, Song L, Yan B, Slusher BS, Zhuo J, Ooi LL, Lee CG, Mancuso A, McCallion AS, Le A, Milone MC, Rayport S, Felsher  DW,  Dang CV. Targeted inhibition of tumor-specific  glutaminase diminishes cell-autonomous tumorigenesis . J Clin Invest . 2015 Jun;125(6):2293-306 .

[10]Gross MI, Demo SD, Dennison JB, Chen L, Chernov- Rogan T, Goyal B, Janes JR, Laidig GJ, Lewis ER, Li J, Mackinnon AL, Parlati F, Rodriguez ML, Shwonek PJ, Sjogren EB, Stanton TF, Wang T, Yang J, Zhao F, Bennett MK . Antitumor activity of the glutaminase inhibitor CB-839 in triple- negative breast cancer. Mol Cancer Ther. 2014 Apr ;13(4):890-901 .

[11]Song M, Kim SH, Im CY, Hwang HJ. Recent Development of Small Molecule Glutaminase Inhibitors . Curr Top Med Chem . 2018;18(6):432-443 .

[12]Vazquez A, Kamphorst JJ, Markert EK, Schug ZT, Tardito S, Gottlieb E . Cancer metabolism at a glance . J Cell Sci . 2016 Sep 15;129(18):3367-73 .

[13]Menendez JA, Lupu R . Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis . Nat Rev Cancer. 2007 Oct;7(10):763-77 .

[14]Flavin R, Peluso S, Nguyen PL, Loda M . Fatty acid synthase as a potential therapeutic target in cancer. Future Oncol . 2010 Apr ;6(4):551-62 .

[15]Losman JA, Looper RE, Koivunen P, Lee S, Schneider RK, McMahon C, Cowley GS, Root DE, Ebert BL, Kaelin WG Jr. (R)-2- hydroxyglutarate is sufficient to promote leukemogenesis and its effects are revers- ible . Science . 2013 Mar 29;339(6127):1621-5 .

[16]Rohle D, Popovici- Muller J, Palaskas N, Turcan S, Grommes C, Campos C, Tsoi J, Clark O, Oldrini B, Komisopoulou E, Kunii K, Pedraza A, Schalm S, Silverman L, Miller A, Wang F, Yang H, Chen Y, Kernytsky A, Rosenblum MK, Liu W, Biller SA, Su SM, Brennan CW, Chan TA, Graeber TG, Yen KE, Mellinghoff IK . An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells . Science . 2013 May 3;340(6132):626-30 .

[17]Wang F, Travins J, DeLaBarre B, Penard- Lacronique V, Schalm S, Hansen E, Straley K, Kernytsky A, Liu W, Gliser C, Yang H, Gross S, Artin E, Saada V, Mylonas E, Quivoron C, Popovici- Muller J, Saunders JO, Salituro FG, Yan S, Murray S, Wei W, Gao Y, Dang L, Dorsch M, Agresta S, Schenkein DP, Biller SA, Su SM, de Botton S, Yen KE . Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation . Science . 2013 May 3;340(6132):622-6 .

[18]Grosvenor M, Bulcavage L, Chlebowski RT. Symptoms potentially influencing weight loss in a cancer population . Correlations with primary site, nutritional status, and chemotherapy administration . Cancer. 1989 Jan 15;63(2):330-4 .

[19]Ezeoke CC, Morley JE . Pathophysiology of anorexia in the cancer cachexia syndrome . J Cachexia Sarcopenia Muscle . 2015 Dec;6(4):287-302 .

[20]Dewys WD, Begg C, Lavin PT, Band PR, Bennett JM, Bertino JR, Cohen MH, Douglass HO Jr, Engstrom PF, Ezdinli EZ, Horton J, Johnson GJ, Moertel CG, Oken MM, Perlia C, Rosenbaum C, Silverstein MN, Skeel RT, Sponzo RW, Tormey DC . Prognostic effect of weight loss prior to chemotherapy in cancer patients . Eastern Cooperative Oncology Group. Am J Med . 1980 Oct;69(4):491-7 .

[21]Bosaeus  I,  Daneryd  P,  Lundholm  K .  Dietary  intake,  resting energy expenditure, weight  loss  and survival in cancer patients . J Nutr. 2002 Nov;132(11 Suppl):3465S-3466S .

[22]Vazeille C, Jouinot A, Durand JP, Neveux N, Boudou- Rouquette P, Huillard O, Alexandre J, Cynober L, Goldwasser F. Relation between hypermetabolism, cachexia, and survival in cancer patients: a prospec- tive  study  in  390  cancer  patients  before  initiation  of  anticancer  therapy.  Am  J  Clin  Nutr.  2017 May;105(5):1139- 1147 .

[23]Schein PS, Kisner D, Haller D, Blecher M, Hamosh M . Cachexia of malignancy: potential role of insulin in nutritional management . Cancer. 1979 May;43(5 Suppl):2070-6 .

[24]MARKS PA, BISHOP JS . The glucose metabolism of patients with malignant disease and of normal subjects   as  studied   by   means  of  an   intravenous  glucose  tolerance  test .  J   Clin   Invest .   1957 Feb;36(2):254-64 .

[25]Jasani B, Donaldson LJ, Ratcliffe JG, Sokhi GS . Mechanism of impaired glucose tolerance in patients with neoplasia . Br J Cancer. 1978 Aug;38(2):287-92 .

[26]Fearon KC, Hansell DT, Preston T, Plumb JA, Davies J, Shapiro D, Shenkin A, Calman KC, Burns HJ. Influence of whole body protein turnover rate on resting energy expenditure in patients with cancer. Cancer Res . 1988 May 1;48(9):2590-5 .

[27]Douglas RG, Shaw JH . Metabolic effects of cancer. Br J Surg . 1990 Mar ;77(3):246-54

[28]Mayers JR, Wu C, Clish CB, Kraft P, Torrence ME, Fiske BP, Yuan C, Bao Y, Townsend MK, Tworoger SS, Davidson SM, Papagiannakopoulos T, Yang A, Dayton TL, Ogino S, Stampfer MJ, Giovannucci EL, Qian ZR, Rubinson DA, Ma J, Sesso HD, Gaziano JM, Cochrane BB, Liu S, Wactawski-Wende J, Manson JE, Pollak MN, Kimmelman AC, Souza A, Pierce K, Wang TJ, Gerszten RE, Fuchs CS, Vander Heiden MG, Wolpin BM . Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarci- noma development . Nat Med . 2014 Oct;20(10):1193- 1198 .

[29]Donaldson SS, Lenon RA . Alterations of nutritional status: impact of chemotherapy and radiation therapy. Cancer. 1979 May;43(5 Suppl):2036-52 .

[30]de  Haas  EC,  Oosting  SF,  Lefrandt  JD, Wolffenbuttel  BH,  Sleijfer  DT,  Gietema  JA . The  metabolic syndrome in cancer survivors . Lancet Oncol . 2010 Feb;11(2):193-203 .

[31]Chemaitilly W, Cohen LE, Mostoufi - Moab S, Patterson BC, Simmons JH, Meacham LR, van Santen HM, Sklar   CA .   Endocrine   Late   Effects   in   Childhood   Cancer   Survivors .   J   Clin   Oncol .   2018   Jul 20;36(21):2153-2159 .

[32]Islami F, Goding Sauer A, Miller KD, Siegel RL, Fedewa SA, Jacobs EJ, McCullough ML, Patel AV, Ma J, Soerjomataram I, Flanders WD, Brawley OW, Gapstur SM, Jemal A . Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States . CA Cancer J Clin .

2018 Jan;68(1):31-54 .

[33]Faulds  MH,  Dahlman-Wright  K .  Metabolic  diseases  and  cancer  risk .  Curr  Opin  Oncol .  2012 Jan;24(1):58-61 .

[34]Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K; International Agency for Research on Cancer Handbook Working Group. Body Fatness and Cancer--Viewpoint of the IARC Working Group. N Engl J Med . 2016 Aug 25;375(8):794-8 .

[35]Whiteman DC, Wilson LF. The fractions of cancer attributable to modifiable factors: A global review. Cancer Epidemiol . 2016 Oct;44:203-221 .

[36]Wilson LF, Antonsson A, Green AC, Jordan SJ, Kendall BJ, Nagle CM, Neale RE, Olsen CM, Webb PM, Whiteman DC . How many cancer cases and deaths are potentially preventable? Estimates for Australia in 2013. Int J Cancer. 2018 Feb 15;142(4):691-701 .

[37]Michels  KB,  Ekbom  A .  Caloric  restriction  and  incidence  of  breast  cancer.  JAMA .  2004  Mar 10;291(10):1226-30 .

[38]Lv M, Zhu X, Wang H, Wang F, Guan W. Roles of caloric restriction, ketogenic diet and intermittent fasting during initiation, progression and metastasis of cancer in animal models: a systematic review and meta-analysis . PLoS One . 2014 Dec 11;9(12):e115147 .

[39]Hursting SD, Lavigne JA, Berrigan D, Perkins SN, Barrett JC . Calorie restriction, aging, and cancer prevention: mechanisms of action and applicability to humans . Annu Rev Med . 2003;54:131-52 .               [40]Poff AM, Ari C, Seyfried TN, D'Agostino DP. The ketogenic diet and hyperbaric oxygen therapy prolong survival in mice with systemic metastatic cancer. PLoS One . 2013 Jun 5;8(6):e65522 .

[41]Weber DD, Aminzadeh-Gohari S, Tulipan J, Catalano L, Feichtinger RG, Kofler B . Ketogenic diet in the treatment of cancer - Where do we stand? Mol Metab. 2020 Mar ;33:102- 121 .

[42]Chen M, Zhang J, Sampieri K, Clohessy JG, Mendez L, Gonzalez- Billalabeitia E, Liu XS, Lee YR, Fung J, Katon JM, Menon AV, Webster KA, Ng C, Palumbieri MD, Diolombi MS, Breitkopf SB, Teruya- Feldstein J, Signoretti  S,  Bronson  RT,  Asara  JM,  Castillo- Martin  M,  Cordon-Cardo  C,  Pandolfi  PP.  An  aberrant SREBP-dependent   lipogenic   program   promotes   metastatic   prostate   cancer.   Nat   Genet .   2018 Feb;50(2):206-218 .

[43]Llaverias G, Danilo C, Wang Y, Witkiewicz AK, Daumer K, Lisanti MP, Frank PG . A Western-type diet accelerates tumor progression in an autochthonous mouse model of prostate cancer. Am J Pathol . 2010 Dec;177(6):3180-91 .

[44]Kalaany NY, Sabatini DM . Tumours with PI3K activation are resistant to dietary restriction . Nature . 2009 Apr 9;458(7239):725-31 .

[45]Sullivan MR, Mattaini KR, Dennstedt EA, Nguyen AA, Sivanand S, Reilly MF, Meeth K, Muir A, Darnell AM, Bosenberg MW, Lewis CA, Vander Heiden MG . Increased Serine Synthesis Provides an Advantage for Tumors Arising in Tissues Where Serine Levels Are Limiting . Cell Metab. 2019 Jun 4;29(6):1410- 1421 .e4 .

[46]Kanarek N, Petrova B, Sabatini DM . Dietary modifications for enhanced cancer therapy. Nature . 2020 Mar ;579(7800):507-517 .

[47]Gallagher EJ, LeRoith D . Hyperinsulinaemia in cancer. Nat Rev Cancer. 2020 Nov;20(11):629-644 .       [48]Nencioni A, Caffa I, Cortellino S, Longo VD . Fasting and cancer : molecular mechanisms and clinical application . Nat Rev Cancer. 2018 Nov;18(11):707-719 .

[49]Gao X, Sanderson SM, Dai Z, Reid MA, Cooper DE, Lu M, Richie JP Jr, Ciccarella A, Calcagnotto A, Mikhael PG, Mentch SJ, Liu J, Ables G, Kirsch DG, Hsu DS, Nichenametla SN, Locasale JW. Dietary methi- onine  influences  therapy  in  mouse  cancer  models  and  alters  human  metabolism .  Nature .  2019 Aug;572(7769):397-401 .

[50]Maddocks ODK, Athineos D, Cheung EC, Lee P, Zhang T, van den Broek NJF, Mackay GM, Labuschagne CF, Gay D, Kruiswijk F, Blagih J, Vincent DF, Campbell KJ, Ceteci F, Sansom OJ, Blyth K, Vousden KH . Modulating the therapeutic response of tumours to dietary serine and glycine starvation . Nature . 2017 Apr 19;544(7650):372-376 .

[51]Maddocks OD, Berkers CR, Mason SM, Zheng L, Blyth K, Gottlieb E, Vousden KH . Serine starvation induces   stress   and   p53-dependent   metabolic   remodelling   in   cancer   cells .   Nature .   2013   Jan 24;493(7433):542-6 .

[52]Gravel SP, Hulea L, Toban N, Birman E, Blouin MJ, Zakikhani M, Zhao Y, Topisirovic I, St- Pierre J, Pollak  M .  Serine  deprivation  enhances  antineoplastic  activity  of  biguanides .  Cancer  Res .  2014  Dec 15;74(24):7521-33 .

[53]Guo H, Lishko VK, Herrera H, Groce A, Kubota T, Hoffman RM . Therapeutic tumor-specific cell cycle block induced by methionine starvation in vivo. Cancer Res . 1993 Dec 1;53(23):5676-9 .

[54]Hoshiya Y, Guo H, Kubota T, Inada T, Asanuma F, Yamada Y, Koh J, Kitajima M, Hoffman RM . Human tumors are methionine dependent in vivo. Anticancer Res . 1995 May-Jun;15(3):717-8 .

[55]Pavlova NN, Thompson CB . The Emerging Hallmarks of Cancer Metabolism . Cell Metab. 2016 Jan 12;23(1):27-47 .

[56]Vander  Heiden  MG,  DeBerardinis  RJ.  Understanding  the  Intersections  between  Metabolism  and Cancer Biology. Cell . 2017 Feb 9;168(4):657-669 .

[57]Teicher  BA,  Linehan  WM,  Helman  LJ.  Targeting  cancer  metabolism .  Clin  Cancer  Res .  2012  Oct 15;18(20):5537-45 .

[58]Luengo A, Gui DY, Vander Heiden MG . Targeting Metabolism for Cancer Therapy. Cell Chem Biol . 2017 Sep 21;24(9):1161- 1180 .

[59]Vernieri C, Casola S, Foiani M, Pietrantonio F, de Braud F, Longo V. Targeting Cancer Metabolism: Dietary and Pharmacologic Interventions . Cancer Discov. 2016 Dec;6(12):1315- 1333 .

[60]Kirschner MW. The meaning of systems biology. Cell . 2005 May 20;121(4):503-504 .

[61]Showalter  MR,  Cajka  T,  Fiehn  O .  Epimetabolites:  discovering  metabolism  beyond  building  and burning . Curr Opin Chem Biol . 2017 Feb;36:70-76 .

[62]Nunes SC . Tumor Microenvironment - Selective Pressures Boosting Cancer Progression . Adv Exp Med Biol . 2020;1219:35-49 .

[63]Mayers JR, Wu C, Clish CB, Kraft P, Torrence ME, Fiske BP, Yuan C, Bao Y, Townsend MK, Tworoger SS, Davidson SM, Papagiannakopoulos T, Yang A, Dayton TL, Ogino S, Stampfer MJ, Giovannucci EL, Qian ZR, Rubinson DA, Ma J, Sesso HD, Gaziano JM, Cochrane BB, Liu S, Wactawski-Wende J, Manson JE, Pollak MN, Kimmelman AC, Souza A, Pierce K, Wang TJ, Gerszten RE, Fuchs CS, Vander Heiden MG, Wolpin BM . Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarci- noma development . Nat Med . 2014 Oct;20(10):1193- 1198 .

[64]Locasale JW, Melman T, Song S, Yang X, Swanson KD, Cantley LC, Wong ET, Asara JM . Metabolomics of  human  cerebrospinal  fluid  identifies  signatures  of  malignant  glioma .  Mol  Cell  Proteomics .  2012 Jun;11(6):M111 .014688 .

[65]Liu X, Romero IL, Litchfield LM, Lengyel E, Locasale JW. Metformin Targets Central Carbon Metabo-

lism and Reveals Mitochondrial Requirements in Human Cancers . Cell Metab. 2016 Nov 8;24(5):728-739 .